Expression of nNOS and soluble guanylate cyclase in schizophrenic brain

NeuroReport

Volumn 15, Issue 4, 2004, Pages 677-680

  Baba, Hajime ^a   Suzuki, Toshihito ^a   Arai, Heii ^a   Emson, Piers C ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Frontal cortex; Guanylate cyclase; Nitric oxide; Real time PCR; Schizophrenia

Indexed keywords

COMPLEMENTARY DNA; GUANYLATE CYCLASE; MESSENGER RNA; NEUROLEPTIC AGENT; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; RISPERIDONE;

ADULT; AGED; ARTICLE; AUTOPSY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ADULT; BRAIN CHEMISTRY; FEMALE; GUANYLATE CYCLASE; HUMANS; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PREFRONTAL CORTEX; PROTEIN SUBUNITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SCHIZOPHRENIA; UP-REGULATION;

EID: 1842556339     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200403220-00020     Document Type: Article

References (24)

1. Dawson TM and Snyder SH. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci 14, 5147-5159 (1994).
2. Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T et al. Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 261, 7236-7241 (1986).
3. Collier J and Vallance P. Second messenger role for NO widens to nervous and immune systems. Trends Pharmacol Sci 10, 427-431 (1989).
4. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Rad Res 31, 577-596 (1999).
5. Javitt DC and Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148, 1301-1308 (1991).
6. Thornberg SA and Saklad SR. A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 16, 82-93 (1996).
7. Duncan GE, Zorn S and Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 4, 418-428 (1999).
8. Bujas-Bobanovic M, Robertson HA and Dursun SM. Effects of nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester on phencydidine-induced effects in rats. Eur J Pharmacol 409, 57-65 (2000).
9. Bujas-Bobanovic M, Bird DC, Robertson HA and Dursun SM. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol 130, 1005-1012 (2000).
10. Sherman AD, Hegwood TS, Baruah S and Waziri R. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol Psychiatry 30, 1191-1198 (1991).
11. Akbarian S, Bunney WE, Pottkin SG, Wigal SB, Hagman JO et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50, 169-177(1993).
12. Akbarian S, Vinuela A, Kim JJ, Pottkin SG, Bunney WE and Jones EG. Distorted distribution of nicotinamide-adenine dinucleotide phosphate- diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development Arch Gen Psychiatry 50, 178-187 (1993).
13. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D et al. Nitric oxide synthase-containing neurons in the hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83, 867-875 (1998).
14. Karson CN, Griffin WS, Mrak RE, Husain M, Dawson TM et al. Nitric oxide synthase (NOS) in schizophrenia: increase in cerebellar vermis. Mol Chem Neuropathol 27, 275-284 (1996).
15. Bernstein HG, Krell D, Braunewell KH, Baumann B, Gundelfinger ED et al. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J Neurocytol 30, 661-670 (2001).
16. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J and Hirsch SR. Elevated platelet calcium metabolization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 212, 375-380 (1995).
17. Das I, Khan NS, Puri BK and Hirsch SR. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci Lett 215, 209-211 (1996).
18. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull R et al. Gene expression analysis in schizophrenia: reproducible upregulation of several members of the apolipoprotein L family located in a high susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci USA 99, 4680-4685 (2002).
19. Ogilvie P, Schilling K, Billingsley ML and Schmidt HH. Induction and variants of neuronal nitric oxide synthase type I during synaptogenesis. FASEB J 9, 799-806 (1995).
20. Xing G, Chavko M, Zhang LX, Yang S and Post RM. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 58, 21-30 (2002).
21. Khan NS, Das I, Puri BK, de Belleroche J and Hirsch SR. Presence of a nitric oxide inhibitor in schizophrenic subjects plasma. Schizophr Res 15, 62-63 (1995).
22. Das I, Ramchand CN, Gliddon A and Hirsch SR. Nitric oxide, free radicals and polyamines may have a role in the membrane pathology of schizophrenia. Neuropsychobiology 37, 65-67 (1998).
23. Srivastava N, Barthwel MK, Dalal PK, Agarwal AK, Nag D et al. Nitrite content and antioxidant enzyme level in the blood of schizophrenia patients. Psychopharmacology 158, 140-145 (2001).
24. Gattaz WF, Cramer H and Beckmann H. Low CSF concentration of cyclic GMP in schizophrenia. Br J Psychiatry 142, 288-291 (1983).